These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1331205)

  • 21. Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity.
    Jones RN
    Am J Med; 1992 Apr; 92(4A):52S-57S. PubMed ID: 1316072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
    Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postantibiotic effects of E-4868 and OPC-17116.
    Sanford MD; Jones RN
    J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
    [No Abstract]   [Full Text] [Related]  

  • 24. [Susceptibility of clinically-isolated bacteria strains to respiratory quinolones and evaluation of antimicrobial agent efficacy by Monte Carlo simulation].
    Kosaka T; Yamada Y; Kimura T; Kodama M; Fujitomo Y; Masaki N; Toshiaki K; Keisuke S; Fujita N
    Jpn J Antibiot; 2016 Feb; 69(1):27-40. PubMed ID: 27290828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro activity of OPC-17116 against bacterial enteric pathogens.
    Arduino RC; Frosolono M; Murray BE
    J Antimicrob Chemother; 1994 Sep; 34(3):403-7. PubMed ID: 7829414
    [No Abstract]   [Full Text] [Related]  

  • 26. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R; Brenwald NP; Andrews JM; Boswell F
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.
    Marco F; Jones RN; Hoban DJ; Pignatari AC; Yamane N; Frei R
    J Antimicrob Chemother; 1994 Mar; 33(3):647-54. PubMed ID: 8040130
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():1-8. PubMed ID: 9433650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Fernandes PB; Chu DT; Bower RR; Jarvis KP; Ramer NR; Shipkowitz N
    Antimicrob Agents Chemother; 1986 Feb; 29(2):201-8. PubMed ID: 3521473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Drugs Exp Clin Res; 1992; 18(8):311-7. PubMed ID: 1338041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
    Esposito S; Noviello S; Ianniello F
    J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.
    Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR
    J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sparfloxacin worldwide in vitro literature: isolate data available through 1994.
    Cohen MA; Yoder SL; Talbot GH
    Diagn Microbiol Infect Dis; 1996 Jun; 25(2):53-64. PubMed ID: 8882890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bactericidal properties of moxifloxacin and post-antibiotic effect.
    Boswell FJ; Andrews JM; Wise R; Dalhoff A
    J Antimicrob Chemother; 1999 May; 43 Suppl B():43-9. PubMed ID: 10382875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics.
    Chin NX; Neu HC
    J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bactericidal kinetics and postantibiotic effect of sparfloxacin against selected species of respiratory pathogens.
    Speciale A; Blandino G; Nicolosi VM; Siracusa V; Caccamo F
    J Chemother; 1995 Dec; 7(6):530-4. PubMed ID: 8667038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.
    Wise R; Andrews JM
    J Antimicrob Chemother; 1999 Nov; 44(5):679-88. PubMed ID: 10552986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.